We here describe the clinical and histopathologic characteristics of sarcomas with FUS/EWSR1-TFCP2 fusions, which were categorized as spindle cell/sclerosing RMS in the most recent WHO classification, provide a comprehensive multi-omics portrait of these tumors, including two benign precursor lesions, and present the oncogenic properties and associated therapeutic vulnerabilities of underlying genetic alterations. This evidence concerns the gene TFCP2 and sarcoma.